Table 5. Factors Associated with All-Cause Mortality.
| Variables | Univariate models, HR (95%CI), p | Multivariate models, HR (95%CI), p | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All (n = 1197) | No prior ADIs at baseline (n = 951) | All (n = 1197) | No prior ADIs at baseline (n = 951) | |||||||||
| Gender male | 3.61 | (1.52–8.57) | 0.004* | 8.02 | (1.89–34.1) | 0.005* | 1.14 | (0.37–3.51) | 0.82 | 5.52 | (0.64–47.4) | 0.12 |
| Age 20–29 | 1 | 1 | 1 | 1 | ||||||||
| Age 30–39 | 1.69 | (0.74–3.83) | 0.21 | 2.76 | (0.77–9.92) | 0.12 | 1.16 | (0.43–3.13) | 0.78 | 1.85 | (0.36–9.60) | 0.47 |
| Age 40–49 | 2.5 | (0.87–7.22) | 0.09 | 5.23 | (1.17–23.4) | 0.03* | 2.69 | (0.85–8.55) | 0.09 | 5.91 | (1.06–32.9) | 0.043* |
| Age over 50 | 4.53 | (1.69–12.1) | 0.003* | 11.0 | (2.74–43.9) | 0.01* | 7.39 | (1.90–28.8) | 0.004* | 11.7 | (1.75–77.6) | 0.011* |
| Injection drug use | 2.00 | (1.09–3.67) | 0.026* | 1.38 | (0.59–3.23) | 0.46 | 1.76 | (0.61–5.09) | 0.30 | 0.93 | (0.19–4.55) | 0.93 |
| HBs antigen positive | 1.48 | (0.69–3.20) | 0.32 | 2.54 | (1.05–6.12) | 0.38 | 1.72 | (0.69–4.26) | 0.24 | 2.48 | (0.81–7.60) | 0.11 |
| Anti-HCV antibody positive | 1.80 | (0.96–3.39) | 0.07 | 1.24 | (0.54–2.83) | 0.61 | 1.99 | (0.60–6.54) | 0.26 | 1.79 | (0.39–8.21) | 0.46 |
| CD4<200 at baseline | 9.64 | (1.31–70.8) | 0.026* | 5.95 | (0.78–45.3) | 0.85 | 6.12 | (0.81–46.3) | 0.08 | 5.12 | (0.66–39.9) | 0.12 |
| Prior ADI at baseline | 2.96 | (1.60–5.46) | 0.001* | - | 2.03 | (0.96–4.27) | 0.06 | - | ||||
HR: hazard ratio; CI: confidential interval; ADI: AIDS-defining illness; HBs antigen: hepatitis B surface antigen; HCV: hepatitis C virus
Note:
* Statistically significant (P<0.05)